Source: Business Standard
Bengaluru-based Anthem Biosciences made a blockbuster debut on the Indian stock exchanges, listing at a 27% premium over its issue price. The ₹3,395 crore IPO received massive investor interest, driven by the company’s position as one of India’s top biotech contract manufacturers (CRDMO).
With advanced facilities catering to fermentation-based APIs, biologics, and high-value small molecules, Anthem is expanding aggressively with new plants in Karnataka and Hosur. Backed by US FDA and global approvals, over 80% of its revenue comes from exports, making it a vital player in India’s pharma manufacturing ambitions.
Analysts call Anthem a “China-plus-one” success story as it helps global pharma reduce dependence on Chinese suppliers.
